title: The PCSK9 Inhibitors: A Novel Therapeutic Target Enters Clinical Practice.
abstract: There is a critical need for alternative, potent agents that can reduce low-density lipoprotein cholesterol (LDL-C) levels in patients with heterozygous familial hyperlipidemia and statin intolerance and those not reaching lipid-lowering treatment goals who are at high risk for cardiovascular (CV) events. The first proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor was approved in July 2015 by the US Food and Drug Administration as an adjunct to diet and maximally tolerated statin therapy for treatment of adults with heterozygous familial hyperlipidemia or clinical atherosclerotic CV disease, who require additional lowering of LDL-C levels. In clinical trials, PCSK9 inhibitors have been shown to reduce LDL-C levels by as much as 60% to 70% when administered as monotherapy or as an add-on treatment to statins and other lipid-lowering therapies. In studies of PCSK9 genetic mutations, loss of function in the PCSK9 allele was associated with a relative decrease of 88% in the risk for atherosclerotic CV events during 15 years of patient follow-up. The use of PCSK9 inhibitors may eventually support the LDL-C hypothesis that the lower the LDL-C level, the lower the CV risk. Although some recent clinical practice guidelines have deemphasized the importance of numeric LDL-C targets, many clinicians are reluctant to discard them, and this position is supported by recent clinical evidence. We eagerly await the results of the ODYSSEY, FOURIER, and SPIRE clinical outcome trials, which we anticipate will provide further validation that "lower is better" with respect to reducing LDL-C levels and improving clinical outcomes.
authors.affiliation: Dr Lepor is Clinical Professor of Medicine, Geffen School of Medicine, University of California, and Faculty Member, Cedars-Sinai Heart Institute, Los Angeles, CA.
authors.forename: Norman E
authors.initials: NE
authors.lastname: Lepor
authors.affiliation: Dr Kereiakes is Medical Director, the Christ Hospital Heart and Vascular Center, and the Carl and Edyth Lindner Center for Research and Education at the Christ Hospital, Cincinnati, OH, and Professor of Clinical Medicine, Ohio State University, Columbus.
authors.forename: Dean J
authors.initials: DJ
authors.lastname: Kereiakes
keywords: LDL-C hypothesis; PCSK9 inhibitors; alirocumab; bococizumab; clinical guidelines; clinical studies; evolocumab; familial hypercholesterolemia; low-density lipoprotein cholesterol; statin treatment; unmet needs
references.citation: J Am Coll Cardiol. 2014 Jun 17;63(23 ):2541-8
references.pmid: 24694531
references.citation: Future Cardiol. 2014 Mar;10 (2):183-99
references.pmid: 24762246
references.citation: Int J Cardiol. 2014 Sep;176(1):55-61
references.pmid: 25037695
references.citation: Nat Genet. 2003 Jun;34(2):154-6
references.pmid: 12730697
references.citation: J Am Coll Cardiol. 2004 Jun 2;43(11):2142-6
references.pmid: 15172426
references.citation: Eur Heart J. 2015 May 14;36(19):1186-94
references.pmid: 25687353
references.citation: Lancet. 2015 Jan 24;385(9965):341-50
references.pmid: 25282520
references.citation: Cardiovasc Drugs Ther. 2014 Jun;28(3):281-9
references.pmid: 24842558
references.citation: J Am Coll Cardiol. 2014 Aug 12;64(6):601-12
references.pmid: 25104531
references.citation: Ann Intern Med. 1971 Jan;74(1):1-12
references.pmid: 5539274
references.citation: Am J Epidemiol. 2004 Sep 1;160(5):407-20
references.pmid: 15321837
references.citation: Circulation. 2014 Jun 24;129(25 Suppl 2):S1-45
references.pmid: 24222016
references.citation: N Engl J Med. 2006 Mar 23;354(12 ):1264-72
references.pmid: 16554528
references.citation: N Engl J Med. 2015 Apr 16;372(16):1489-99
references.pmid: 25773378
references.citation: Eur Heart J. 2014 Apr;35(15):960-8
references.pmid: 24639424
references.citation: J Clin Lipidol. 2014 Nov-Dec;8(6):554-61
references.pmid: 25499937
references.citation: Lancet. 2015 Jan 24;385(9965):331-40
references.pmid: 25282519
references.citation: N Engl J Med. 2012 Mar 22;366(12 ):1108-18
references.pmid: 22435370
references.citation: N Engl J Med. 2015 Jun 18;372(25):2387-97
references.pmid: 26039521
references.citation: Am Heart J. 2015 Jun;169(6):906-915.e13
references.pmid: 26027630
references.citation: Ann Intern Med. 2015 Jul 7;163(1):40-51
references.pmid: 25915661